Amedeo Smart

Free Medical Literature Service


 

Amedeo

COVID-19

  Free Subscription

Articles published in
Life Sci
    August 2022
  1. HOSSEINZADEH A, Bagherifard A, Koosha F, Amiri S, et al
    Melatonin effect on platelets and coagulation: Implications for a prophylactic indication in COVID-19.
    Life Sci. 2022;307:120866.
    >> Share

    July 2022
  2. ALI MA, El-Tahan RA, Kamel MA, Matar NA, et al
    The diabetogenic effects of chronic supplementation of vitamin C or E in rats: Interplay between liver and adipose tissues transcriptional machinery of lipid metabolism.
    Life Sci. 2022 Jul 18:120812. doi: 10.1016/j.lfs.2022.120812.
    >> Share

  3. MALEKINEJAD Z, Baghbanzadeh A, Nakhlband A, Baradaran B, et al
    Recent clinical findings on the role of kinase inhibitors in COVID-19 management.
    Life Sci. 2022 Jul 13:120809. doi: 10.1016/j.lfs.2022.120809.
    >> Share

  4. MAZUMDER S, Bindu S, De R, Debsharma S, et al
    Emerging role of mitochondrial DAMPs, aberrant mitochondrial dynamics and anomalous mitophagy in gut mucosal pathogenesis.
    Life Sci. 2022 Jul 1:120753. doi: 10.1016/j.lfs.2022.120753.
    >> Share

  5. PANDA M, Kalita E, Singh S, Kumar K, et al
    MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies.
    Life Sci. 2022 Jul 1:120761. doi: 10.1016/j.lfs.2022.120761.
    >> Share

    June 2022
  6. GUPTA A, Jayakumar MN, Saleh MA, Kannan M, et al
    SARS-CoV-2-infection induced growth factors play differential roles in COVID-19 pathogenesis.
    Life Sci. 2022 Jun 11:120703. doi: 10.1016/j.lfs.2022.120703.
    >> Share

    May 2022
  7. PATIL PJ, Sutar SS, Usman M, Patil DN, et al
    Exploring bioactive peptides as potential therapeutic and biotechnology treasures: A contemporary perspective.
    Life Sci. 2022;301:120637.
    >> Share

  8. FERNANDES MF, Chan JZ, Hung CCJ, Tomczewski MV, et al
    Effect of cannabidiol on apoptosis and cellular interferon and interferon-stimulated gene responses to the SARS-CoV-2 genes ORF8, ORF10 and M protein.
    Life Sci. 2022;301:120624.
    >> Share

  9. HUANG DY, Wang GM, Ke ZR, Zhou Y, et al
    Megakaryocytes in pulmonary diseases.
    Life Sci. 2022 May 1:120602. doi: 10.1016/j.lfs.2022.120602.
    >> Share

    April 2022
  10. YOUNG LJ, Antwi-Boasiako S, Ferrall J, Wold LE, et al
    Genetic and non-genetic risk factors associated with atrial fibrillation.
    Life Sci. 2022;299:120529.
    >> Share

    March 2022
  11. MAZIDIMORADI A, Alemzadeh E, Alemzadeh E, Salehiniya H, et al
    The effect of polyunsaturated fatty acids on the severity and mortality of COVID patients: A systematic review.
    Life Sci. 2022 Mar 28:120489. doi: 10.1016/j.lfs.2022.120489.
    >> Share

  12. NADEALI Z, Rezaei FM, Aria H, Nikpour P, et al
    Possible role of pannexin 1 channels and purinergic receptors in the pathogenesis and mechanism of action of SARS-CoV-2 and therapeutic potential of targeting them in COVID-19.
    Life Sci. 2022 Mar 11:120482. doi: 10.1016/j.lfs.2022.120482.
    >> Share

  13. MENENDEZ SG, Martin Gimenez VM, Holick MF, Barrantes FJ, et al
    COVID-19 and neurological sequelae: Vitamin D as a possible neuroprotective and/or neuroreparative agent.
    Life Sci. 2022;297:120464.
    >> Share

    February 2022
  14. BHATT AN, Kumar A, Rai Y, Kumari N, et al
    Glycolytic inhibitor 2-deoxy-d-glucose attenuates SARS-CoV-2 multiplication in host cells and weakens the infective potential of progeny virions.
    Life Sci. 2022;295:120411.
    >> Share

  15. SAGHAFI N, Rezaee SA, Momtazi-Borojeni AA, Tavasolian F, et al
    The therapeutic potential of regulatory T cells in reducing cardiovascular complications in patients with severe COVID-19.
    Life Sci. 2022;294:120392.
    >> Share

    January 2022
  16. TAN DX, Reiter RJ
    Mechanisms and clinical evidence to support melatonin's use in severe COVID-19 patients to lower mortality.
    Life Sci. 2022 Jan 30:120368. doi: 10.1016/j.lfs.2022.120368.
    >> Share

  17. PORTALES AE, Mustafa ER, McCarthy CI, Cornejo MP, et al
    ACE2 internalization induced by a SARS-CoV-2 recombinant protein is modulated by angiotensin II type 1 and bradykinin 2 receptors.
    Life Sci. 2022;293:120284.
    >> Share

  18. SILVA MG, Falcoff NL, Corradi GR, Alfie J, et al
    Renin-angiotensin system blockade on angiotensin-converting enzyme 2 and TMPRSS2 in human type II pneumocytes.
    Life Sci. 2022 Jan 12:120324. doi: 10.1016/j.lfs.2022.120324.
    >> Share

    December 2021
  19. ZAKI MO, Elsherbiny DA, Salama M, Azab SS, et al
    Potential role of Drug Repositioning Strategy (DRS) for management of tauopathy.
    Life Sci. 2021 Dec 30:120267. doi: 10.1016/j.lfs.2021.120267.
    >> Share

    October 2021
  20. ULASOV AV, Rosenkranz AA, Georgiev GP, Sobolev AS, et al
    Nrf2/Keap1/ARE signaling: Towards specific regulation.
    Life Sci. 2021 Oct 31:120111. doi: 10.1016/j.lfs.2021.120111.
    >> Share

  21. AHMAD S, Hatmal MM, Lambuk L, Al-Hatamleh MAI, et al
    The role of TNFR2(+) Tregs in COVID-19: An overview and a potential therapeutic strategy.
    Life Sci. 2021;286:120063.
    >> Share

    August 2021
  22. LUTHRA R, Kaur S, Bhandari K
    Applications of CRISPR as a potential therapeutic.
    Life Sci. 2021 Aug 25:119908. doi: 10.1016/j.lfs.2021.119908.
    >> Share

  23. PAL D, Goyal J, Sharma U, Sharma A, et al
    Mesenchymal stem cells in SARS-CoV-2 infection: A hype or hope.
    Life Sci. 2021;284:119901.
    >> Share

  24. AMRUTA N, Engler-Chiurazzi EB, Murray-Brown IC, Gressett TE, et al
    In Vivo protection from SARS-CoV-2 infection by ATN-161 in k18-hACE2 transgenic mice.
    Life Sci. 2021;284:119881.
    >> Share

    June 2021
  25. ADITYA RAO SJ, Shetty NP
    Evolutionary selectivity of amino acid is inspired from the enhanced structural stability and flexibility of the folded protein.
    Life Sci. 2021 Jun 28:119774. doi: 10.1016/j.lfs.2021.119774.
    >> Share

  26. CHAN Y, Ng SW, Singh SK, Gulati M, et al
    Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective.
    Life Sci. 2021;280:119744.
    >> Share

  27. LEE MC, Chen YK, Tsai-Wu JJ, Hsu YJ, et al
    Zinc supplementation augments the suppressive effects of repurposed NF-kappaB inhibitors on ACE2 expression in human lung cell lines.
    Life Sci. 2021;280:119752.
    >> Share

    May 2021
  28. KARSLI E, Sabirli R, Altintas E, Canacik O, et al
    Soluble P-selectin as a potential diagnostic and prognostic biomarker for COVID-19 disease: A case-control study.
    Life Sci. 2021 May 17:119634. doi: 10.1016/j.lfs.2021.119634.
    >> Share

  29. CHATTERJEE S, Mishra S, Chowdhury KD, Ghosh CK, et al
    Various theranostics and immunization strategies based on nanotechnology against Covid-19 pandemic: An interdisciplinary view.
    Life Sci. 2021 May 12:119580. doi: 10.1016/j.lfs.2021.119580.
    >> Share

  30. OKUYAN HM, Dogan S, Bal T, Cabalak M, et al
    Beclin-1, an autophagy-related protein, is associated with the disease severity of COVID-19.
    Life Sci. 2021 May 10:119596. doi: 10.1016/j.lfs.2021.119596.
    >> Share

    April 2021
  31. DAWRE S, Maru S
    Human respiratory viral infections: Current status and future prospects of nanotechnology-based approaches for prophylaxis and treatment.
    Life Sci. 2021 Apr 26:119561. doi: 10.1016/j.lfs.2021.119561.
    >> Share

  32. GHAEBI M, Tahmasebi S, Jozghorbani M, Sadeghi A, et al
    Risk factors for adverse outcomes of COVID-19 patients: Possible basis for diverse responses to the novel coronavirus SARS-CoV-2.
    Life Sci. 2021;277:119503.
    >> Share

  33. CHEUDJEU A
    Antiviral strategies should focus on stimulating the biosynthesis of heparan sulfates, not their inhibition.
    Life Sci. 2021;277:119508.
    >> Share

  34. PARIS GC, de A Azevedo A, Ferreira AL, de A Azevedo YM, et al
    Therapeutic potential of mesenchymal stem cells in multiple organs affected by COVID-19.
    Life Sci. 2021 Apr 15:119510. doi: 10.1016/j.lfs.2021.119510.
    >> Share

    March 2021
  35. TAHMASEBI S, Saeed BQ, Temirgalieva E, Yumashev AV, et al
    Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2.
    Life Sci. 2021 Mar 28:119437. doi: 10.1016/j.lfs.2021.119437.
    >> Share

  36. PRASANNA P, Rathee S, Upadhyay A, Sulakshana S, et al
    Nanotherapeutics in the treatment of acute respiratory distress syndrome.
    Life Sci. 2021;276:119428.
    >> Share

  37. POTJE SR, Costa TJ, Fraga-Silva TFC, Martins RB, et al
    Heparin prevents in vitro glycocalyx shedding induced by plasma from COVID-19 patients.
    Life Sci. 2021;276:119376.
    >> Share

  38. POSADAS-SANCHEZ R, Sanchez-Munoz F, Guzman-Martin CA, Hernandez-Diaz Couder A, et al
    Dipeptidylpeptidase-4 levels and DPP4 gene polymorphisms in patients with COVID-19. Association with disease and with severity.
    Life Sci. 2021;276:119410.
    >> Share

  39. CHENG X, Xin S, Chen Y, Li L, et al
    Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: A multicentral retrospective study.
    Life Sci. 2021;275:119371.
    >> Share

  40. DIMBATH E, Maddipati V, Stahl J, Sewell K, et al
    Implications of microscale lung damage for COVID-19 pulmonary ventilation dynamics: A narrative review.
    Life Sci. 2021;274:119341.
    >> Share

  41. HASSANZADEH P
    The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing.
    Life Sci. 2021 Mar 4:119289. doi: 10.1016/j.lfs.2021.119289.
    >> Share

    February 2021
  42. CHIAPPALUPI S, Salvadori L, Vukasinovic A, Donato R, et al
    Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: Hypotheses and perspectives.
    Life Sci. 2021 Feb 23:119251. doi: 10.1016/j.lfs.2021.119251.
    >> Share

  43. SANTIESTEBAN-LORES LE, Amamura TA, da Silva TF, Midon LM, et al
    A double edged-sword - The Complement System during SARS-CoV-2 infection.
    Life Sci. 2021;272:119245.
    >> Share

  44. KUNNUMAKKARA AB, Rana V, Parama D, Banik K, et al
    COVID-19, cytokines, inflammation, and spices: How are they related?
    Life Sci. 2021 Feb 16:119201. doi: 10.1016/j.lfs.2021.119201.
    >> Share

  45. SAVIRON-CORNUDELLA R, Villalba A, Esteban LM, Tajada M, et al
    Screening of severe acute respiratory syndrome coronavirus-2 infection during labor and delivery using polymerase chain reaction and immunoglobulin testing.
    Life Sci. 2021 Feb 9:119200. doi: 10.1016/j.lfs.2021.119200.
    >> Share

    January 2021
  46. AGHBASH PS, Eslami N, Shamekh A, Entezari-Maleki T, et al
    SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis.
    Life Sci. 2021;270:119124.
    >> Share

  47. WANG SC, Wang YF
    Cardiovascular protective properties of oxytocin against COVID-19.
    Life Sci. 2021 Jan 26:119130. doi: 10.1016/j.lfs.2021.119130.
    >> Share

  48. ABID SA, Suhail A, Al-Kadmy IMS, Sattar AA, et al
    Biosensors as a future diagnostic approach for COVID-19.
    Life Sci. 2021 Jan 25:119117. doi: 10.1016/j.lfs.2021.119117.
    >> Share

  49. MANSOUR BS, Salem NA, Kader GA, Abdel-Alrahman G, et al
    Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model.
    Life Sci. 2021;269:119099.
    >> Share

  50. FAWAD M, Mubarik S, Malik SS, Ren J, et al
    Statistical analysis of COVID-19 infection caused by environmental factors: Evidence from Pakistan.
    Life Sci. 2021 Jan 18:119093. doi: 10.1016/j.lfs.2021.119093.
    >> Share

  51. MEIDANINIKJEH S, Sabouni N, Marzouni HZ, Bengar S, et al
    Monocytes and macrophages in COVID-19: Friends and foes.
    Life Sci. 2021;269:119010.
    >> Share

  52. HAROUN RA, Osman WH, Eessa AM
    Interferon-gamma-induced protein 10 (IP-10) and serum amyloid A (SAA) are excellent biomarkers for the prediction of COVID-19 progression and severity.
    Life Sci. 2021 Jan 14:119019. doi: 10.1016/j.lfs.2021.119019.
    >> Share

  53. ZHANG Z, Wang T, Liu F, Zhu A, et al
    The proteomic characteristics of airway mucus from critical ill COVID-19 patients.
    Life Sci. 2021;269:119046.
    >> Share

    December 2020
  54. KOTNALA S, Dhasmana A, Kashyap VK, Chauhan SC, et al
    A bird eye view on cystic fibrosis: An underestimated multifaceted chronic disorder.
    Life Sci. 2020 Dec 28:118959. doi: 10.1016/j.lfs.2020.118959.
    >> Share

  55. HIRAWAT R, Saifi MA, Godugu C
    Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications.
    Life Sci. 2020;267:118923.
    >> Share

  56. SILVEIRA MM, Moreira GMSG, Mendonca M
    DNA vaccines against COVID-19: Perspectives and challenges.
    Life Sci. 2020 Dec 19:118919. doi: 10.1016/j.lfs.2020.118919.
    >> Share

  57. P KM, Sivashanmugam K, Kandasamy M, Subbiah R, et al
    Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-beta signalling in COVID-19 survivors.
    Life Sci. 2020;266:118883.
    >> Share

  58. LU J, Hou Y, Ge S, Wang X, et al
    Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro.
    Life Sci. 2020;266:118889.
    >> Share

    November 2020
  59. LA MARCA G, Barp J, Frenos S, Mugelli A, et al
    Thermal inactivation of SARS COVID-2 virus: Are steam inhalations a potential treatment?
    Life Sci. 2020 Nov 21:118801. doi: 10.1016/j.lfs.2020.118801.
    >> Share

  60. SABIRLI R, Koseler A, Goren T, Turkcuer I, et al
    High GRP78 levels in Covid-19 infection: A case-control study.
    Life Sci. 2020 Nov 18:118781. doi: 10.1016/j.lfs.2020.118781.
    >> Share

  61. LANG Y, Chen K, Li Z, Li H, et al
    The nucleocapsid protein of zoonotic betacoronaviruses is an attractive target for antiviral drug discovery.
    Life Sci. 2020 Nov 12:118754. doi: 10.1016/j.lfs.2020.118754.
    >> Share

    October 2020
  62. DHAUNDIYAL A, Kumari P, Jawalekar SS, Chauhan G, et al
    Is highly expressed ACE 2 in pregnant women "a curse" in times of COVID-19 pandemic?
    Life Sci. 2020 Oct 28:118676. doi: 10.1016/j.lfs.2020.118676.
    >> Share

  63. SHRESTHA DB, Budhathoki P, Syed NI, Rawal E, et al
    Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis.
    Life Sci. 2020 Oct 26:118663. doi: 10.1016/j.lfs.2020.118663.
    >> Share

  64. BAKADIA BM, Boni BOO, Ahmed AAQ, Yang G, et al
    The impact of oxidative stress damage induced by the environmental stressors on COVID-19.
    Life Sci. 2020 Oct 26:118653. doi: 10.1016/j.lfs.2020.118653.
    >> Share

  65. PAN ZY, Chang YX, Han N, Hou FY, et al
    Short-term high-dose gavage of hydroxychloroquine changes gut microbiota but not the intestinal integrity and immunological responses in mice.
    Life Sci. 2020 Oct 22:118450. doi: 10.1016/j.lfs.2020.118450.
    >> Share

  66. MORRIS G, Bortolasci CC, Puri BK, Olive L, et al
    Preventing the development of severe CoVID 19 by modifying immunothrombosis.
    Life Sci. 2020 Oct 20:118617. doi: 10.1016/j.lfs.2020.118617.
    >> Share

  67. BAILLY C, Vergoten G
    Mechanistic insights into dimethyl cardamonin-mediated pharmacological effects: A double control of the AMPK-HMGB1 signaling axis.
    Life Sci. 2020 Oct 18:118601. doi: 10.1016/j.lfs.2020.118601.
    >> Share

  68. YADAV P, Vats R, Bano A, Bhardwaj R, et al
    Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics.
    Life Sci. 2020;263:118588.
    >> Share

  69. SATARKER S, Nampoothiri M
    Involvement of the nervous system in COVID-19: The bell should toll in the brain.
    Life Sci. 2020 Oct 6:118568. doi: 10.1016/j.lfs.2020.118568.
    >> Share

  70. MORRIS G, Athan E, Walder K, Bortolasci CC, et al
    Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?
    Life Sci. 2020;262:118541.
    >> Share

    September 2020
  71. VITIELLO A, Ferrara F
    Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19.
    Life Sci. 2020;262:118510.
    >> Share

  72. PENG W, Wu H, Tan Y, Li M, et al
    Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019.
    Life Sci. 2020;262:118496.
    >> Share

  73. SADEGHI S, Soudi S, Shafiee A, Hashemi SM, et al
    Mesenchymal stem cell therapies for COVID-19: Current status and mechanism of action.
    Life Sci. 2020;262:118493.
    >> Share

  74. UNUDURTHI SD, Luthra P, Bose RJC, McCarthy J, et al
    Cardiac inflammation in COVID-19: Lessons from heart failure.
    Life Sci. 2020 Sep 21:118482. doi: 10.1016/j.lfs.2020.118482.
    >> Share

  75. BELHASSAN A, En-Nahli F, Zaki H, Lakhlifi T, et al
    Assessment of effective imidazole derivatives against SARS-CoV-2 main protease through computational approach.
    Life Sci. 2020 Sep 18:118469. doi: 10.1016/j.lfs.2020.118469.
    >> Share

  76. VINAYAGAM S, Sattu K
    SARS-CoV-2 and coagulation disorders in different organs.
    Life Sci. 2020;260:118431.
    >> Share

  77. KHATRI R, Gupta RK, Vats P, Bansal V, et al
    Subclinical elevated B-type Natriuretic Peptide (BNP) indicates endothelial dysfunction contributing to hypoxia susceptibility in healthy individuals.
    Life Sci. 2020 Sep 11:118408. doi: 10.1016/j.lfs.2020.118408.
    >> Share

  78. CHAUDHRY SN, Hazafa A, Mumtaz M, Kalsoom U, et al
    New insight on possible vaccine development against SARS-CoV-2.
    Life Sci. 2020 Sep 11:118421. doi: 10.1016/j.lfs.2020.118421.
    >> Share

  79. DUERR GD, Heine A, Hamiko M, Zimmer S, et al
    Parameters predicting COVID-19-induced myocardial injury and mortality.
    Life Sci. 2020 Sep 9:118400. doi: 10.1016/j.lfs.2020.118400.
    >> Share

    August 2020
  80. CACCIAPUOTI S, De Rosa A, Gelzo M, Megna M, et al
    Immunocytometric analysis of COVID patients: A contribution to personalized therapy?
    Life Sci. 2020 Aug 29:118355. doi: 10.1016/j.lfs.2020.118355.
    >> Share

  81. CHEUDJEU A
    Correlation of D-xylose with severity and morbidity-related factors of COVID-19 and possible therapeutic use of D-xylose and antibiotics for COVID-19.
    Life Sci. 2020;260:118335.
    >> Share

  82. WANG F, Zheng S, Zheng C, Sun X, et al
    Attaching clinical significance to COVID-19-associated diarrhea.
    Life Sci. 2020;260:118312.
    >> Share

  83. BHAVANA V, Thakor P, Singh SB, Mehra NK, et al
    COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic.
    Life Sci. 2020 Aug 23:118336. doi: 10.1016/j.lfs.2020.118336.
    >> Share

  84. ELFIKY AA, Baghdady AM, Ali SA, Ahmed MI, et al
    GRP78 targeting: Hitting two birds with a stone.
    Life Sci. 2020 Aug 22:118317. doi: 10.1016/j.lfs.2020.118317.
    >> Share

  85. VARGAS-ALARCON G, Posadas-Sanchez R, Ramirez-Bello J
    Variability in genes related to SARS-CoV-2 entry into host cells (ACE2, TMPRSS2, TMPRSS11A, ELANE, and CTSL) and its potential use in association studies.
    Life Sci. 2020;260:118313.
    >> Share

  86. PARVATHANENI V, Gupta V
    Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges.
    Life Sci. 2020 Aug 17:118275. doi: 10.1016/j.lfs.2020.118275.
    >> Share

  87. HOSSEINI FS, Amanlou M
    Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study.
    Life Sci. 2020;258:118205.
    >> Share

  88. MAHENDIRATTA S, Batra G, Sarma P, Kumar H, et al
    Molecular diagnosis of COVID-19 in different biologic matrix, their diagnostic validity and clinical relevance: A systematic review.
    Life Sci. 2020;258:118207.
    >> Share

  89. MOHAMMAD A, Marafie SK, Alshawaf E, Abu-Farha M, et al
    Structural analysis of ACE2 variant N720D demonstrates a higher binding affinity to TMPRSS2.
    Life Sci. 2020 Aug 5:118219. doi: 10.1016/j.lfs.2020.118219.
    >> Share

  90. DAS S, Anu KR, Birangal SR, Nikam AN, et al
    Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review.
    Life Sci. 2020 Aug 3:118202. doi: 10.1016/j.lfs.2020.118202.
    >> Share

  91. MANSOURABADI AH, Sadeghalvad M, Mohammadi-Motlagh HR, Rezaei N, et al
    The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19.
    Life Sci. 2020 Aug 1:118185. doi: 10.1016/j.lfs.2020.118185.
    >> Share

    July 2020
  92. MORRIS G, Bortolasci CC, Puri BK, Olive L, et al
    The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach.
    Life Sci. 2020 Jul 30:118166. doi: 10.1016/j.lfs.2020.118166.
    >> Share

  93. SHARMA K, Morla S, Goyal A, Kumar S, et al
    Computational guided drug repurposing for targeting 2'-O-ribose methyltransferase of SARS-CoV-2.
    Life Sci. 2020 Jul 29:118169. doi: 10.1016/j.lfs.2020.118169.
    >> Share

  94. AKBARI H, Tabrizi R, Lankarani KB, Aria H, et al
    The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
    Life Sci. 2020 Jul 28:118167. doi: 10.1016/j.lfs.2020.118167.
    >> Share

  95. SUT BB
    Molecular profiling of immune cell-enriched Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) interacting protein USP13.
    Life Sci. 2020 Jul 28:118170. doi: 10.1016/j.lfs.2020.118170.
    >> Share

  96. ZHANG J, Wang M, Ding W, Wan J, et al
    The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future.
    Life Sci. 2020;257:118142.
    >> Share

  97. PANIRI A, Akhavan-Niaki H
    Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation.
    Life Sci. 2020 Jul 18:118114. doi: 10.1016/j.lfs.2020.118114.
    >> Share

  98. ZUCKERBERG J, Shaik M, Nelin TD, Widmeier K, et al
    A lung for all: Novel mechanical ventilator for emergency and low-resource settings.
    Life Sci. 2020 Jul 17:118113. doi: 10.1016/j.lfs.2020.118113.
    >> Share

  99. JAFARZADEH A, Chauhan P, Saha B, Jafarzadeh S, et al
    Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
    Life Sci. 2020 Jul 17:118102. doi: 10.1016/j.lfs.2020.118102.
    >> Share

  100. JAMWAL S, Gautam A, Elsworth J, Kumar M, et al
    An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic.
    Life Sci. 2020 Jul 17:118105. doi: 10.1016/j.lfs.2020.118105.
    >> Share

  101. ABBASIFARD M, Khorramdelazad H
    The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics.
    Life Sci. 2020;257:118097.
    >> Share

  102. HAZRA S, Chaudhuri AG, Tiwary BK, Chakrabarti N, et al
    Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis.
    Life Sci. 2020 Jul 14:118096. doi: 10.1016/j.lfs.2020.118096.
    >> Share

  103. ABDIN SM, Elgendy SM, Alyammahi SK, Alhamad DW, et al
    Tackling the cytokine storm in COVID-19, challenges, and hopes.
    Life Sci. 2020 Jul 11:118054. doi: 10.1016/j.lfs.2020.118054.
    >> Share

  104. BEHL T, Kaur I, Bungau S, Kumar A, et al
    The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions.
    Life Sci. 2020;257:118075.
    >> Share

  105. BHARADWAJ S, Lee KE, Dwivedi VD, Kang SG, et al
    Computational insights into tetracyclines as inhibitors against SARS-CoV-2 M(pro) via combinatorial molecular simulation calculations.
    Life Sci. 2020;257:118080.
    >> Share

  106. HAJIVALILI M, Hosseini M, Haji-Fatahaliha M
    Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges.
    Life Sci. 2020 Jul 9:118058. doi: 10.1016/j.lfs.2020.118058.
    >> Share

  107. YAVARPOUR-BALI H, Ghasemi-Kasman M
    Update on neurological manifestations of COVID-19.
    Life Sci. 2020 Jul 8:118063. doi: 10.1016/j.lfs.2020.118063.
    >> Share

  108. STERNBERG A, Naujokat C
    Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination.
    Life Sci. 2020 Jul 6:118056. doi: 10.1016/j.lfs.2020.118056.
    >> Share

    June 2020
  109. BENITEZ-CARDOZA CG, Vique-Sanchez JL
    Potential inhibitors of the interaction between ACE2 and SARS-CoV-2 (RBD), to develop a drug.
    Life Sci. 2020;256:117970.
    >> Share

  110. PANDEY SC, Pande V, Sati D, Upreti S, et al
    Vaccination strategies to combat novel corona virus SARS-CoV-2.
    Life Sci. 2020;256:117956.
    >> Share

  111. HAGE-MELIM LIDS, Federico LB, de Oliveira NKS, Francisco VCC, et al
    Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.
    Life Sci. 2020;256:117963.
    >> Share

  112. BANU N, Panikar SS, Leal LR, Leal AR, et al
    Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications.
    Life Sci. 2020;256:117905.
    >> Share

  113. SIMKO F, Reiter RJ
    Is melatonin deficiency a unifying pathomechanism of high risk patients with COVID-19?
    Life Sci. 2020;256:117902.
    >> Share

  114. KHODIR AE, Samra YA, Said E
    A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.
    Life Sci. 2020 Jun 3:117907. doi: 10.1016/j.lfs.2020.117907.
    >> Share

  115. YAZDANPANAH F, Hamblin MR, Rezaei N
    The immune system and COVID-19: Friend or foe?
    Life Sci. 2020 Jun 2:117900. doi: 10.1016/j.lfs.2020.117900.
    >> Share

  116. PANDEY A, Nikam AN, Shreya AB, Mutalik SP, et al
    Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements.
    Life Sci. 2020 Jun 1:117883. doi: 10.1016/j.lfs.2020.117883.
    >> Share

    May 2020
  117. BANERJEE A, Czinn SJ, Reiter RJ, Blanchard TG, et al
    Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19.
    Life Sci. 2020;255:117842.
    >> Share

  118. TONG PB, Lin LY, Tran TH
    Coronaviruses pandemics: Can neutralizing antibodies help?
    Life Sci. 2020 May 22:117836. doi: 10.1016/j.lfs.2020.117836.
    >> Share

  119. GURUNG AB, Ali MA, Lee J, Farah MA, et al
    Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M(pro) enzyme through in silico approach.
    Life Sci. 2020;255:117831.
    >> Share

  120. RENU K, Prasanna PL, Valsala Gopalakrishnan A
    Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review.
    Life Sci. 2020;255:117839.
    >> Share

  121. MARTIN GIMENEZ VM, Inserra F, Tajer CD, Mariani J, et al
    Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment.
    Life Sci. 2020;254:117808.
    >> Share

  122. KERMALI M, Khalsa RK, Pillai K, Ismail Z, et al
    The role of biomarkers in diagnosis of COVID-19 - A systematic review.
    Life Sci. 2020 May 13:117788. doi: 10.1016/j.lfs.2020.117788.
    >> Share

  123. KERMALI M, Khalsa RK, Pillai K, Ismail Z, et al
    The role of biomarkers in diagnosis of COVID-19 - A systematic review.
    Life Sci. 2020;254:117788.
    >> Share

  124. PATIL VM, Singhal S, Masand N
    A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.
    Life Sci. 2020;254:117775.
    >> Share

  125. POOLADANDA V, Thatikonda S, Godugu C
    The current understanding and potential therapeutic options to combat COVID-19.
    Life Sci. 2020 May 8:117765. doi: 10.1016/j.lfs.2020.117765.
    >> Share

    April 2020
  126. HERRERA EA, Gonzalez-Candia A
    Comment on Melatonin as a potential adjuvant treatment for COVID-19.
    Life Sci. 2020 Apr 30:117739. doi: 10.1016/j.lfs.2020.117739.
    >> Share

  127. BABAPOOR-FARROKHRAN S, Gill D, Walker J, Rasekhi RT, et al
    Myocardial injury and COVID-19: Possible mechanisms.
    Life Sci. 2020;253:117723.
    >> Share

  128. SALLES C
    Correspondence COVID-19: Melatonin as a potential adjuvant treatment.
    Life Sci. 2020 Apr 22:117716. doi: 10.1016/j.lfs.2020.117716.
    >> Share

  129. SHAH B, Modi P, Sagar SR
    In silico studies on therapeutic agents for COVID-19: Drug repurposing approach.
    Life Sci. 2020 Apr 9:117652. doi: 10.1016/j.lfs.2020.117652.
    >> Share

    March 2020
  130. ELFIKY AA
    Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.
    Life Sci. 2020 Mar 25:117592. doi: 10.1016/j.lfs.2020.117592.
    >> Share

    February 2020
  131. ELFIKY AA
    Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
    Life Sci. 2020 Feb 28:117477. doi: 10.1016/j.lfs.2020.117477.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016